Oviva

96 weeks of intervention. Six follow-up visits. 100% digital questionnaire completion. The AMODA trial extension has just completed: the longest follow-up we've run after an initial randomised controlled trial, evaluating Oviva Direkt für Adipositas, our Digital Health Application (DiGA) in Germany. Keeping people consistently engaged for two years meant we could demonstrate the potential and clinical impact of longer intervention periods for digital therapeutics. What's next? Database lock is done, the data is with us, and analysis is now underway. We'll share the findings as soon as they're through. But for now I want to thank everyone at Oviva and beyond who made this possible (full list in the comments) 💚 More to follow!

The conversation around women’s health is rightly becoming more prominent, but metabolic health still needs to be a bigger part of it. For some women, PMOS, formerly known as PCOS, can affect far more than weight, influencing energy, mood, confidence, cycles and day-to-day wellbeing. One patient on Oviva’s Tier 3 weight-management pathway recently shared that her treatment helped ease her PMOS symptoms. With support from Oviva’s clinical team, including nutrition, behaviour change, psychological support and physical activity guidance, she was able to make changes that improved how she felt in daily life. Bilie-Jo's experience reflects what we see across the programme. After nine months on Oviva’s Tier 3 pathway, female patients reported improvements in overall health, mental health, quality of life and ability to carry out physical activity. For many patients, weight-related conditions sit alongside other long-term health challenges, from PMOS and type 2 diabetes to cardiovascular risk and mental wellbeing. Tier 3 weight management has an important role to play here, supporting better health across multiple conditions, not weight alone. https://lnkd.in/ezZivM4q

The recording of our main stage session at HLTH Europe is now live & worth a watch if you missed it. A few things I said on stage: Software can be copied in a quarter. Trust builds slowly. That's why reimbursement was non-negotiable for us from day one and why a decade inside the system is now the thing nobody can replicate. We were told to go to the US about a hundred times. We said no every time. Staying narrow on a few very large conditions in Europe and going deep rather than broad. That discipline is what got us to over one million patients. The founder's paradox: you have to keep letting go of things you thought you were great at (and still know exactly when to dive back in). Grateful for the conversation with Stanislas Niox-Chateau and Molly Gilmartin. 🎥 Full session in the comments

Wie kommt die #DiGA in die Versorgung? Spoiler: Die Qualität einer DiGA alleine reicht nicht aus. Oft ist sogar die Kommerzialisierung einer DiGA anspruchsvoller als ihre Entwicklung. Sagt Kai Eberhardt, CEO und Mitbegründer von Oviva. Hinter Oviva steht eine DiGA, die Erwachsene mit Adipositas unterstützt. Die App ist dauerhaft im DiGA-Verzeichnis gelistet und wird von den gesetzlichen Krankenkassen erstattet. Eberhardt weiß also, wovon er spricht, weshalb wir ihn gebeten haben, seine Erfahrungen mit uns zu teilen. Was heißt denn herausfordernd genau? Hersteller müssen Patientinnen und Patienten erreichen, Ärztinnen und Ärzte überzeugen und gleichzeitig steigende Evidenzanforderungen erfüllen. Das kann mit einem umfassenden Omnichannel-Marketing-Konzept funktionieren. "Dazu gehören digitale Kanäle wie Meta, Google und YouTube. Gleichzeitig haben wir aber auch TV, Radio und Out-of-Home-Kampagnen getestet. Je nach Zielgruppe und Situation funktionieren unterschiedliche Kanäle unterschiedlich gut." Eine wichtige Zielgruppe sind Patientinnen und Patienten selbst. "Von unserer Seite aus gehören Patientinnen und Patienten zu den wichtigsten Zugangswegen überhaupt. Darum machen wir Patientinnen und Patienten aktiv darauf aufmerksam, dass es diese Versorgungsangebote gibt und dass sie sie über ihre Ärztin oder ihren Arzt erhalten können." Und: Evidenz alleine reicht nicht aus. Diese stehe bei Ärztinnen und Ärzten zwar an erster Stelle und sei maßgeblicher Faktor für den Erfolg, schnell folge aber die Frage nach dem Praxisalltag. "Wie aufwendig ist die Integration? Muss die Ärztin oder der Arzt die App erklären? Entsteht zusätzliche Arbeit?" Fazit: Die Entwicklung einer DiGA ist nur ein Teil der Aufgabe. "Viele unterschätzen, wie aufwendig die Kommerzialisierung ist. Man investiert bereits erhebliche Summen in Entwicklung, Studien und regulatorische Anforderungen. Danach beginnt aber erst die eigentliche Herausforderung." Mehr erfährst Du im ungekürzten Interview hier 👇 https://lnkd.in/dytEbgGH Wenn Expertenwissen wie dieses Dich interessiert, dann solltest Du unseren kostenfreien Newsletter zu abonnieren. Den Link findest du auf unserer Homepage: healthrelations.de. Und folge uns unbedingt hier auf diesem Kanal und werde Teil der Community. Wir freuen uns auf Dich und Deine Perspektiven.

Obesity is one of the biggest drivers of demand across the NHS, contributing to long-term conditions and increasing pressure on frontline services. Data from Oviva shows the impact that effective, scalable support can have. After nine months, face-to-face GP visits decreased by 43%, remote contacts fell by 48%, and there was a 63% increase in patients reporting no GP contacts. The programme combines weight-loss medication with digital, clinician-led behavioural support, helping patients achieve clinically meaningful outcomes while reducing their need for healthcare appointments. Among semaglutide users, patients lost an average of 12.4% of their body weight, with 72% losing at least 10% of their baseline weight. Effective obesity care should not add to frontline pressure. It should help eligible patients access structured support earlier, improve outcomes, and reduce avoidable demand on GP appointments. That is the opportunity digital weight-management services can deliver at scale.

Obesity is no longer just a health challenge. It is a workforce challenge too, with new analysis suggesting more than 600,000 people in Britain may be out of work because of obesity. This reflects what we see in Oviva’s own data. In a study of NHS patients receiving weight-loss medication alongside digital wraparound care, overall sick days fell by 45%, while extended sick leave more than halved. The message is clear: effective obesity treatment can help people improve their health, take fewer sick days and stay active in work and daily life. That requires more than medication alone. Scalable obesity care must combine clinical oversight, behavioural support and digital tools that help patients build sustainable routines over time. Read more below. https://lnkd.in/eBpt4SMZ

Obesity care is most effective when it reflects the complexity of patients’ lives. For many patients, sustainable weight management is not just about diet or medication. It requires support with behaviour change, mental wellbeing, movement, confidence and the practical routines that shape day-to-day health. That is why Oviva’s multidisciplinary model matters. Our team brings together dietitians, psychologists and exercise specialists to provide holistic support that helps patients build healthier habits in a way that works for them. As one GP recently shared, this joined-up approach offers “a truly holistic way to support patients”, with shorter waiting times also helping eligible patients access support sooner. Discover more about our weight management pathways here: https://lnkd.in/e8SvJHCE

This week our Clinical Lead Dietitian, Louise Bula, presented to hundreds of GPs at the Pulse 365 Virtual Event on a question coming up everywhere: how do we make GLP-1s deliver lasting results? Her message was clear - medication alone isn't enough. Pairing GLP-1 medications with evidence-based nutrition and behavioural support is how we help people manage their weight for the long term. Want to explore how Oviva's Tier 3 service could support your patients? Book a call with one of our Service Engagement Managers: https://lnkd.in/eBpSrNqa